Your session is about to expire
What is Zytiga
Approved as Treatment by the FDA
Abiraterone, commonly known as Zytiga, is approved by the FDA for 6 uses such as Castration and Prostatic Neoplasms .Effectiveness
When to interrupt dosage
The suggested dosage of Zytiga is contingent upon the diagnosed health state. The dose varies, based on the administration approach outlined in the table beneath.Warnings
There are 20 known major drug interactions with Zytiga.Zytiga Novel Uses: Which Conditions Have a Clinical Trial Featuring Zytiga?
30 ongoing clinical trials are investigating the potential of Zytiga to manage Castration-Resistant Prostate Cancer.Zytiga Reviews: What are patients saying about Zytiga?
Patient Q&A Section about zytiga
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How long do you take Zytiga?
"Many people with prostate cancer must take Zytiga for 2-3 years, resulting in hundreds of thousands of dollars in treatment costs."
How long can you survive Zytiga?
"Patients who took Zytiga had an average lifespan of 35.3 months, while those who took the placebo only lived for 30.1 months on average."
What are the side effects of Zytiga?
"If you are feeling any of the following symptoms, you may be experiencing menopause: fatigue, joint pain, high blood pressure, nausea, leg or feet swelling, low blood potassium levels, hot flushes, diarrhea."
What is the side effect of Zytiga?
"ZYTIGA® may cause some serious side effects. These include high blood pressure, low potassium levels in the blood, fluid retention, and irregular heartbeats."
Is Zytiga a form of chemotherapy?
"Zytiga (abiraterone acetate) is used to treat men with metastasized prostate cancer, alongside prednisone. It is not a form of chemotherapy, despite being used to treat cancer."
What does the drug Zytiga do?
"ZYTIGA is a prescription medication that is to be used in conjunction with prednisone. It is specifically meant to treat prostate cancer that has spread to other areas of the body in male patients."